Last updated: July 17, 2026

Application No. 18/559,732

REGULATING T CELL IMMUNE RESPONSE THROUGH IGF-I RECEPTOR (IGF-1R)

Non-Final OA

Filed

Nov 08, 2023

Priority

May 11, 2021 — provisional 63/187,295 +1 more

Examiner

WEIDNER, ADAM M

Art Unit

1675

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

The Regents of the University of Michigan

OA Round

1 (Non-Final)

This examiner grants 64% of cases after interview

— +34.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 643 resolved cases, 2023–2026

Examiner Intelligence

WEIDNER, ADAM M View full profile →

Grants 64% of resolved cases

Career Allowance Rate

409 granted / 643 resolved

+3.6% vs TC avg

Strong +34% interview lift

Without

With

+34.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 4m

Avg Prosecution

38 currently pending

Career history

675

Total Applications

across all art units

Statute-Specific Performance

§101

3.4%

-36.6% vs TC avg

§103

41.7%

+1.7% vs TC avg

§102

9.8%

-30.2% vs TC avg

§112

14.5%

-25.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 643 resolved cases

Prosecution Timeline

Nov 08, 2023

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/522,503

Patent 12678424

METHOD FOR PREVENTING AND/OR TREATING AGING-ASSOCIATED COGNITIVE IMPAIRMENT AND NEUROINFLAMMATION

2y 7m to grant Granted Jul 14, 2026

18/344,757

Patent 12653861

METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE

2y 11m to grant Granted Jun 16, 2026

17/609,309

Patent 12649792

BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND PD1 WITH ENHANCED T CELL-MEDIATED CYTOTOXIC EFFECTS ON TUMOR CELLS

4y 7m to grant Granted Jun 09, 2026

17/511,420

Patent 12595312

CD133-BINDING AGENTS AND USES THEREOF

4y 5m to grant Granted Apr 07, 2026

17/910,040

Patent 12577303

SIRPALPHA-TARGETING ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND PREPARATION AND APPLICATION THEREOF

3y 6m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

64%

Grant Probability

98%

With Interview (+34.0%)

2y 4m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 643 resolved cases by this examiner. Grant probability derived from career allowance rate.